Pharma fears “lack of focus” on no-deal Brexit preparations

supply. That is the view of Merck KGaA chief executive and President of European pharma's EFPIA, Stefan Oschmann, who says that the pharma industry has “been concerned by a certain ... While the situation at the EU-UK border remains unclear, two-thirds

Keytruda combo outshines Opdivo in kidney cancer

The data sets Merck &Co up to steal market share away from it rival, and the firm has already has filed the combination with the FDA. ... There is another contender in the checkpoint inhibitor field which could play a role: Pfizer and Merck KGaA’s

Industry aghast as EU Parliament backs biosimilar rule change

In an open letter to European institutions, the president of the EFPIA trade body, Merck KGaA chairman and CEO Stefan Oschmann (below), says the EP’s provisions “diverge significantly from the

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms. GlaxoSmithKline yesterday demonstrated a new boldness in its business development, signing a multi-billion dollar alliance with Germany’s Merck on next-generation immunotherapy. ... acquisition of Tesaro and

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]